ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Shattuck raises $118 million for bifunctional proteins

by Ryan Cross
June 20, 2020 | APPEARED IN VOLUME 98, ISSUE 24

Shattuck Labs, a protein-engineering firm founded in 2016, has raised $118 million in series B financing to support clinical trials of its fusion protein therapies for cancer. Shattuck creates bifunctional protein therapies. One end of the engineered protein includes an immune checkpoint receptor, which takes the brakes off the immune system. The other end includes a protein that binds to tumor necrosis factor, to hit the gas on the immune system. Shattuck is working with Takeda Pharmaceutical to test the idea in the clinic.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment